Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Gout Detected from a Simple Blood Sample

By Labmedica International staff writers
Posted on 31 Oct 2013
Print article
An in vitro diagnostic test, which detects active Gout disease from samples of whole blood, has been launched in Europe.

The CE marked GoutiFind test takes a new approach to Gout diagnosis. Based on a key scientific discovery of how our immune system reacts to uric acid crystal deposition in joints, the GoutiFind test measures the cellular immune response to the deposits. No special clinical setting is required for the GoutiFind test. A fresh blood sample drawn in a physician’s office or clinical laboratory is all that is required for the GoutiFind test.

The GoutiFind test is offered throughout the EU as a diagnostic service by Boulder Diagnostics (Mellrichstadt, Germany) clinical diagnostic service laboratory. The GoutiFind test detects active Gout disease without employing the unreliable determination of the uric acid level. It therefore provides a noninvasive reliable diagnosis of Gout disease.

The GoutiFind test can replace the invasive joint puncture method for Gout detection and thus make reliable Gout diagnosis available to a much broader range of medical institutions and physician practices. The test is based on measuring the cellular immune response to a specific challenge with a Gout stimulus.

"The GoutiFind test simplifies and makes Gout diagnosis more broadly available," commented Dr. Wolfgang Pieken, CEO of Boulder Diagnostics Inc., and added, "the GoutiFind test is the second product from our technology platform that queries the trained immunity for active disease."

"At our clinical laboratory in Mellrichstadt, Germany, we now accept whole blood samples for Gout detection by the GoutiFind method," stated Dr. Anton Waldherr, laboratory physician of Boulder Diagnostics Europe GmbH.

Related Links:

Boulder Diagnostics



Print article
Abbott Diagnostics

Channels

Lab Tech.

view channel
Image: The nano-DLD chip (2 cm x 2 cm) mounted in a microfluidic jig. The technology allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array that allows sorting a microscopic waterfall of nanoparticles, separating particles by size down to 20 nanometer resolution (Photo courtesy of IBM Research).

Lab-on-a-Chip Technology Breaks New Bioparticle Separation Record

Scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale down to 20 nanometers in diameter, a scale that gives access to important... Read more

Industry News

view channel

Critical Care Diagnostics Market Worth USD 1.29 Billion By 2024

The global critical care diagnostics (CCD) market will grow at a lucrative rate over the next few years to reach USD 1.29 billion by 2024, driven by the rapid awareness and acknowledgment of these tests by physicians and patients, rise in geriatric population and chronic health conditions, use of telehealth services in... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.